BioCentury
ARTICLE | Finance

Ebb & Flow

October 25, 2004 7:00 AM UTC

A flurry of listings on AIM this month has been driven by a set of investors that differs significantly from investors in the types of biotech companies that would list on the main London market.

While some of the latter investors have been indulging in hallway chatter that the AIM stories will draw money away from main market companies, there is no reason to believe that this would be the case. But the AIM flurry does point out the extent that value degradation has chiseled away at long-time public names in the U.K. and the Continent...